Nanosphere, Inc. (Nasdaq:NSPH),
manufactures and markets an advanced molecular diagnostics platform, the Verigene(r)
System, for direct genomic and ultra-sensitive protein detection, announced
today that it will provide cancer related data through three abstracts at the
45th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be
held in Orlando, Fla. from May 29 to June 2, 2009.
The abstracts discuss the use of biomarkers in pre-clinical development, cancer
recurrence and clinical needs of novel biomarkers.
Abstract ID: e14594 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Ultra-Sensitive detection of biomarkers and applications
in pharmaceutical discovery and development. Example application to rat Cardiac
troponin I assay via nanoparticle probes."
Verisens(tm) cTnI Cardiotoxicity Assay is an in vitro diagnostic assay for
the high-sensitivity detection and quantification of rat cardiac troponin I
(cTnI). The assay is intended to be performed as a testing service for research
For additional information, please contact Nanosphere at firstname.lastname@example.org
Abstract ID: e16146 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Detection of prostate cancer recurrence using an ultrasensitive
nanoparticle-based PSA assay."
Verisens(tm) PSA is an in vitro diagnostic assay for the high-sensitivity detection
and quantification of prostate specific antigen (PSA). The assay was developed
in collaboration with the International Institute for Nanotechnology at Northwestern
University. It is intended to be performed as a testing service for research
use only (see research-use notification below).
For additional information, please contact Nanosphere at email@example.com
Abstract ID: e22222 - Published: May 14, 2009, 6:00 p.m.
Abstract Title: "Biomarkers in cancer: Survey of diagnostic needs."
Nanosphere, Inc. is required by the U.S. Food and Drug Administration (FDA)
to certify in writing that its customers, who purchase or who are supplied with
products labeled "For Research Use Only," acknowledge and understand
that such products are not for use in diagnostic or therapeutic procedures.
Tests performed with in vitro products intended for "Research Use Only"
are tests used in a preclinical or nonclinical setting. While research tests
may be performed using either clinical or nonclinical materials, research use
devices have no intended clinical use and the testing performed is not designed
to provide data addressing or demonstrating safety and effectiveness. We advise
our customers to monitor the use of these products, to ensure that they are
used for research purposes only. Please contact Nanosphere if you have questions.
The following link provides access to these abstracts: http://abstractsearch.asco.org/cgi-bin/ts.pl?index=442064&query=nanosphere&opt=exact